Sign Up
Stories
Akari Therapeutics: Merger and Progress
Share
Analyst Recommendations Impact Diverse C...
Arcus Biosciences Boosts Inducement Gran...
Arcus Biosciences Employs Inducement Gra...
ABIO ARCA Revenue Analysis
ARCA Biopharma Revenue Insights
Acquisition Progress Amid Safety Concern
Overview
API
Akari Therapeutics discloses full-year 2023 financial results, finalizes merger with Peak Bio Inc., and advances Phase 3 trial for nomacopan in pediatric HSCT-TMA.
Ask a question
How could Akari's financial standing influence its ability to innovate and bring new therapies to market in the future?
How might the merger with Peak Bio Inc. impact Akari Therapeutics' market competitiveness and research capabilities?
What potential implications could the positive progress in the Phase 3 trial for nomacopan have on the treatment landscape for pediatric HSCT-TMA patients?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jan 2024
Feb 2024
Mar 2024
Coverage